Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson, Oskar LU orcid ; Batrla, Richard ; Brix, Britta ; Carrillo, Maria C. ; Corradini, Veronika ; Edelmayer, Rebecca M. ; Esquivel, Rianne N. ; Hall, Christina ; Lawson, John and Bastard, Nathalie Le , et al. (2021) In Alzheimer's and Dementia 17(9). p.1575-1582
Abstract

The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for AD, including the early phases of the disease. However, between-center differences in pre-analytical procedures may contribute to variability in measurements across laboratories. To resolve this issue, a workgroup was led by the Alzheimer's Association with experts from both academia and industry. The aim of the group was to develop a simplified and standardized pre-analytical protocol for CSF collection and handling before analysis for routine clinical use, and ultimately to ensure high diagnostic performance and... (More)

The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for AD, including the early phases of the disease. However, between-center differences in pre-analytical procedures may contribute to variability in measurements across laboratories. To resolve this issue, a workgroup was led by the Alzheimer's Association with experts from both academia and industry. The aim of the group was to develop a simplified and standardized pre-analytical protocol for CSF collection and handling before analysis for routine clinical use, and ultimately to ensure high diagnostic performance and minimize patient misclassification rates. Widespread application of the protocol would help minimize variability in measurements, which would facilitate the implementation of unified cut-off levels across laboratories, and foster the use of CSF biomarkers in AD diagnostics for the benefit of the patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, Amyloid Beta, Biomarkers, Cerebrospinal Fluid, CSF, Diagnosis, Fresh CSF, Frozen CSF, Handling, Measurements, Pre-Analytical, Tau
in
Alzheimer's and Dementia
volume
17
issue
9
pages
1575 - 1582
publisher
Wiley
external identifiers
  • scopus:85103663941
  • pmid:33788410
ISSN
1552-5260
DOI
10.1002/alz.12316
language
English
LU publication?
yes
id
5027c9b8-5b10-452b-8766-68a5fc077375
date added to LUP
2021-04-14 10:55:39
date last changed
2024-04-20 05:50:30
@article{5027c9b8-5b10-452b-8766-68a5fc077375,
  abstract     = {{<p>The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for AD, including the early phases of the disease. However, between-center differences in pre-analytical procedures may contribute to variability in measurements across laboratories. To resolve this issue, a workgroup was led by the Alzheimer's Association with experts from both academia and industry. The aim of the group was to develop a simplified and standardized pre-analytical protocol for CSF collection and handling before analysis for routine clinical use, and ultimately to ensure high diagnostic performance and minimize patient misclassification rates. Widespread application of the protocol would help minimize variability in measurements, which would facilitate the implementation of unified cut-off levels across laboratories, and foster the use of CSF biomarkers in AD diagnostics for the benefit of the patients.</p>}},
  author       = {{Hansson, Oskar and Batrla, Richard and Brix, Britta and Carrillo, Maria C. and Corradini, Veronika and Edelmayer, Rebecca M. and Esquivel, Rianne N. and Hall, Christina and Lawson, John and Bastard, Nathalie Le and Molinuevo, José Luis and Nisenbaum, Laura K. and Rutz, Sandra and Salamone, Salvatore J. and Teunissen, Charlotte E. and Traynham, Christopher and Umek, Robert M. and Vanderstichele, Hugo and Vandijck, Manu and Wahl, Simone and Weber, Christopher J. and Zetterberg, Henrik and Blennow, Kaj}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; Amyloid Beta; Biomarkers; Cerebrospinal Fluid; CSF; Diagnosis; Fresh CSF; Frozen CSF; Handling; Measurements; Pre-Analytical; Tau}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{1575--1582}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau}},
  url          = {{http://dx.doi.org/10.1002/alz.12316}},
  doi          = {{10.1002/alz.12316}},
  volume       = {{17}},
  year         = {{2021}},
}